-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Reiterates Overweight on 10x Genomics, Maintains $14 Price Target

Benzinga·05/15/2025 13:25:38
Listen to the news
Stephens & Co. analyst Mason Carrico reiterates 10x Genomics (NASDAQ:TXG) with a Overweight and maintains $14 price target.